Cartherics Pty Ltd
Peter J. Hudson is an accomplished scientist and leader in the biotechnology sector, currently serving as Chief Scientific Officer at Avipep Pty Ltd and Director of the Victorian Cancer Biologics Consortium since 2008. With a robust background that includes co-founding Cartherics Pty Ltd and Isoclide Medical Pty Ltd, as well as founding and leading Diantron Biomed Pty Ltd, Hudson has significantly advanced the development of cancer-targeted therapies and biopharmaceuticals. Hudson's previous roles include Chief Research Scientist at CSIRO, where several engineered antibody platforms were developed, and Deputy CEO of the CRC for Diagnostics. An elected Fellow of the Australian Academy of Technological Sciences and Engineering, Hudson holds a PhD in Molecular Biology from Cambridge University and a BSc(Hons) in Biochemistry from Adelaide University.
This person is not in the org chart
This person is not in any teams
Cartherics Pty Ltd
Cartherics is a biotechnology company focused on developing innovative cancer therapies. We work to create precisely-defined immunotherapy treatments to combat a variety of cancers. We take a multi-platform approach combining the best components of immune defences utilising gene editing and CAR technology – developing more precise and more accessible treatment options for patients. We are focused on solid tumours and disrupting the tumour microenvironment (TME) to make tumours accessible to immune destruction. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer. We’re developing new forms of solid cancer care treatment - helping patients fight cancer and take back control of their lives.